Pharma Roundup: Cephalon's Strategy, GSK: "No Big M&A," and More

Cephalon's winning business model -- Time and time again, Cephalon buys a drug for cheap and then gives it the resources to become a success, earning big money in the process -- 2009 revenue for the company should top $2 billion. Combined with "superior drug scouting" and "hyperaggressive marketing," it's added up to success, as analyzed in an article from Investor's Business Daily. [Source: Yahoo Finance, via Corey Nahman]

GlaxoSmithKline uninterested in mega-mergers -- "I don't particularly believe that big M&A is going to be a great solution to anything in the next few years," CEO Andrew Witty said. He said GSK is looking for smaller acquisitions that can integrate smoothly with existing operations. [Source: PharmaTimes]
J&J subsidiary Janssen partners with Vanderbilt University -- Janssen, owned by Johnson & Johnson, will pay up to $100 million to Vanderbilt; Vanderbilt, in turn, will develop potential treatments for schizophrenia until they are ready for human trials. [Source: FierceBiotech]

"The amount of revenue generated by the average new medicine is dropping." -- This according to a report from IMS Health. [Source: Forbes, via Corey Nahman]